Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 243,177 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71. Following the transaction, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $674,991,673.97. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Trading Up 3.1%

Shares of NASDAQ ROIV traded up $1.13 during midday trading on Tuesday, hitting $37.37. 6,409,504 shares of the company’s stock were exchanged, compared to its average volume of 5,396,372. Roivant Sciences Ltd. has a 12-month low of $11.54 and a 12-month high of $37.46. The company has a market cap of $26.99 billion, a price-to-earnings ratio of -70.51 and a beta of 1.12. The business’s fifty day moving average price is $34.16 and its two-hundred day moving average price is $30.17.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Equities analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

ROIV has been the subject of a number of analyst reports. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Citigroup raised their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. SBI Securities Co. Ltd. grew its position in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Kestra Advisory Services LLC bought a new position in shares of Roivant Sciences in the 4th quarter worth about $47,000. Parallel Advisors LLC boosted its stake in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after buying an additional 2,665 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.